Clinical Trials Logo

Clinical Trial Summary

The purpose of this observational study is to evaluate the effectiveness and safety of generic imatinib under usual clinical practice in patients of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) patients in chronic phase (CP) in Egypt


Clinical Trial Description

An observational, multi-center, prospective cohort study to assess the effectiveness and safety of generic Imatinib (Carcemia®) in patients with Ph+ CML who are newly diagnosed or patients who will be switched from the reference product (Glivec® ) to Carcemia® where treatment will be prescribed by the investigator in accordance with clinical practice where no visits or intervention(s) additional to the daily practice will be performed. Eligible Ph+ CML patients in both cohorts will be followed up for a total of 18 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03454503
Study type Observational
Source Hikma Pharmaceuticals LLC
Contact
Status Completed
Phase
Start date May 13, 2018
Completion date December 28, 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06427811 - Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation Phase 4